Trastuzumab-deruxtecan in patients with triple-negative metastatic HER2-Low breast cancer: real-world experience in Brazil

Trial Identifier: D9673R00036
Sponsor: AstraZeneca
Collaborator:
Hospital Israelita Albert Einstein
Start Date: December 2023
Primary Completion Date: March 2024
Study Completion Date: March 2024
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Brazil, Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil
Brazil, São Paulo São Paulo, Brazil